Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Giredestrant |
Trade Name | |
Synonyms | RG6171|GDC9545|GDC 9545|GDC-9545) |
Drug Descriptions |
Giredestrant (GDC-9545) is a selective estrogen receptor degrader (SERD) that prevents cell proliferation of ER-positive cells (Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 1023-1023). |
DrugClasses | Hormone - Anti-estrogens 25 |
CAS Registry Number | 1953133-47-5 |
NCIT ID | C147030 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Abemaciclib + Giredestrant | Abemaciclib Giredestrant | 0 | 1 |
Everolimus + Giredestrant | Everolimus Giredestrant | 0 | 2 |
GDC-0077 + Giredestrant | GDC-0077 Giredestrant | 0 | 1 |
Giredestrant | Giredestrant | 0 | 6 |
Giredestrant + Ipatasertib | Giredestrant Ipatasertib | 0 | 1 |
Giredestrant + Palbociclib | Giredestrant Palbociclib | 0 | 3 |
Giredestrant + Pertuzumab/trastuzumab/hyaluronidase-zzxf | Giredestrant Pertuzumab/trastuzumab/hyaluronidase-zzxf | 0 | 1 |
Giredestrant + Ribociclib | Giredestrant Ribociclib | 0 | 1 |